Iovance Biotherapeutics

US · IOVA #1864 by market cap Listed 1970

12.92 -0.05 -0.35%

Live - 5344 symbols - heartbeat 447s ago · 2026-10-08 06:47

Pre-market 12.86 -0.42%

After-hours 12.88 -0.27%

Overnight 12.94 +0.19%

Market cap: 5.85B
P/E (TTM): -18.72
P/B: 7.95
EPS: -1.09
Div yield: 0.00%
52W pos: 82%

Reader sentiment Are you bullish or bearish on IOVA?

Anonymous reader poll. Unscientific, not investment advice.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Founded: 2007
CEO: Dr. Frederick G. Vogt, J.D.
Employees: 975
Headquarters: San Carlos, California, United States of America
Fiscal year end: 12-31
Website: iovance.com

Company profile

Exchange: US
Symbol: IOVA
Market-cap rank: #1864
Listing date: 1970-01-01
Market cap: 5.85B
Float cap: 5.09B
Shares out: 452.97M
Float shares: 394.31M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 06:47:47 · For reference only, not investment advice and not tailored to your situation.